report cover

Relapsed Acute Myeloid Leukemia Drug Market, Global Outlook and Forecast 2023-2030

  • 29 October 2023
  • Life Sciences
  • 111 Pages
  • Report code : 24WT-7840386

Relapsed Acute Myeloid Leukemia Drug and Forecast Market

1 Introduction to Research & Analysis Reports
1.1 Relapsed Acute Myeloid Leukemia Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Relapsed Acute Myeloid Leukemia Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Relapsed Acute Myeloid Leukemia Drug Overall Market Size
2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size: 2022 VS 2030
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales: 2018-2030
3 Company Landscape
3.1 Top Relapsed Acute Myeloid Leukemia Drug Players in Global Market
3.2 Top Global Relapsed Acute Myeloid Leukemia Drug Companies Ranked by Revenue
3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Companies
3.4 Global Relapsed Acute Myeloid Leukemia Drug Sales by Companies
3.5 Global Relapsed Acute Myeloid Leukemia Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Relapsed Acute Myeloid Leukemia Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Players in Global Market
3.8.1 List of Global Tier 1 Relapsed Acute Myeloid Leukemia Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Market Size Markets, 2022 & 2030
4.1.2 aNK Program
4.1.3 AT-9283
4.1.4 BI-836858
4.1.5 Binimetinib
4.1.6 BL-8040
4.1.7 Others
4.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
4.2.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2023
4.2.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2024-2030
4.2.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
4.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
4.3.1 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2023
4.3.2 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2024-2030
4.3.3 By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
4.4 By Type - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2022 & 2030
5.1.2 Clinic
5.1.3 Hospital
5.1.4 Others
5.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
5.2.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2023
5.2.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2024-2030
5.2.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
5.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
5.3.1 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2023
5.3.2 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2024-2030
5.3.3 By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
5.4 By Application - Global Relapsed Acute Myeloid Leukemia Drug Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2022 & 2030
6.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue & Forecasts
6.2.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2023
6.2.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2024-2030
6.2.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
6.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales & Forecasts
6.3.1 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2023
6.3.2 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales, 2024-2030
6.3.3 By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.4.2 By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.4.3 US Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.4.4 Canada Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.4.5 Mexico Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.5.2 By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.5.3 Germany Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.4 France Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.5 U.K. Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.6 Italy Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.7 Russia Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.8 Nordic Countries Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.5.9 Benelux Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.6.2 By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.6.3 China Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.4 Japan Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.5 South Korea Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.6 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.6.7 India Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.7.2 By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.7.3 Brazil Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.7.4 Argentina Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, 2018-2030
6.8.3 Turkey Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8.4 Israel Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8.5 Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
6.8.6 UAE Relapsed Acute Myeloid Leukemia Drug Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 4SC AG
7.1.1 4SC AG Company Summary
7.1.2 4SC AG Business Overview
7.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.1.5 4SC AG Key News & Latest Developments
7.2 AbbVie Inc.
7.2.1 AbbVie Inc. Company Summary
7.2.2 AbbVie Inc. Business Overview
7.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.2.5 AbbVie Inc. Key News & Latest Developments
7.3 Actinium Pharmaceuticals, Inc.
7.3.1 Actinium Pharmaceuticals, Inc. Company Summary
7.3.2 Actinium Pharmaceuticals, Inc. Business Overview
7.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.3.5 Actinium Pharmaceuticals, Inc. Key News & Latest Developments
7.4 Agios Pharmaceuticals, Inc.
7.4.1 Agios Pharmaceuticals, Inc. Company Summary
7.4.2 Agios Pharmaceuticals, Inc. Business Overview
7.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.4.5 Agios Pharmaceuticals, Inc. Key News & Latest Developments
7.5 Amgen Inc.
7.5.1 Amgen Inc. Company Summary
7.5.2 Amgen Inc. Business Overview
7.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.5.5 Amgen Inc. Key News & Latest Developments
7.6 Arog Pharmaceuticals, Inc.
7.6.1 Arog Pharmaceuticals, Inc. Company Summary
7.6.2 Arog Pharmaceuticals, Inc. Business Overview
7.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.6.5 Arog Pharmaceuticals, Inc. Key News & Latest Developments
7.7 Array BioPharma Inc.
7.7.1 Array BioPharma Inc. Company Summary
7.7.2 Array BioPharma Inc. Business Overview
7.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.7.5 Array BioPharma Inc. Key News & Latest Developments
7.8 Astellas Pharma Inc.
7.8.1 Astellas Pharma Inc. Company Summary
7.8.2 Astellas Pharma Inc. Business Overview
7.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.8.5 Astellas Pharma Inc. Key News & Latest Developments
7.9 Astex Pharmaceuticals, Inc.
7.9.1 Astex Pharmaceuticals, Inc. Company Summary
7.9.2 Astex Pharmaceuticals, Inc. Business Overview
7.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.9.5 Astex Pharmaceuticals, Inc. Key News & Latest Developments
7.10 AstraZeneca Plc
7.10.1 AstraZeneca Plc Company Summary
7.10.2 AstraZeneca Plc Business Overview
7.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.10.5 AstraZeneca Plc Key News & Latest Developments
7.11 AVEO Pharmaceuticals, Inc.
7.11.1 AVEO Pharmaceuticals, Inc. Company Summary
7.11.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Business Overview
7.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.11.5 AVEO Pharmaceuticals, Inc. Key News & Latest Developments
7.12 BioLineRx, Ltd.
7.12.1 BioLineRx, Ltd. Company Summary
7.12.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Business Overview
7.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.12.5 BioLineRx, Ltd. Key News & Latest Developments
7.13 Boehringer Ingelheim GmbH
7.13.1 Boehringer Ingelheim GmbH Company Summary
7.13.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Business Overview
7.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.13.5 Boehringer Ingelheim GmbH Key News & Latest Developments
7.14 Boston Biomedical, Inc.
7.14.1 Boston Biomedical, Inc. Company Summary
7.14.2 Boston Biomedical, Inc. Business Overview
7.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.14.5 Boston Biomedical, Inc. Key News & Latest Developments
7.15 Bristol-Myers Squibb Company
7.15.1 Bristol-Myers Squibb Company Company Summary
7.15.2 Bristol-Myers Squibb Company Business Overview
7.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.15.5 Bristol-Myers Squibb Company Key News & Latest Developments
7.16 Calithera Biosciences, Inc.
7.16.1 Calithera Biosciences, Inc. Company Summary
7.16.2 Calithera Biosciences, Inc. Business Overview
7.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.16.5 Calithera Biosciences, Inc. Key News & Latest Developments
7.17 Celgene Corporation
7.17.1 Celgene Corporation Company Summary
7.17.2 Celgene Corporation Business Overview
7.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.17.5 Celgene Corporation Key News & Latest Developments
7.18 Cornerstone Pharmaceuticals, Inc.
7.18.1 Cornerstone Pharmaceuticals, Inc. Company Summary
7.18.2 Cornerstone Pharmaceuticals, Inc. Business Overview
7.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.18.5 Cornerstone Pharmaceuticals, Inc. Key News & Latest Developments
7.19 CTI BioPharma Corp.
7.19.1 CTI BioPharma Corp. Company Summary
7.19.2 CTI BioPharma Corp. Business Overview
7.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Major Product Offerings
7.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales and Revenue in Global (2018-2023)
7.19.5 CTI BioPharma Corp. Key News & Latest Developments
8 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity, Analysis
8.1 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity, 2018-2030
8.2 Relapsed Acute Myeloid Leukemia Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Relapsed Acute Myeloid Leukemia Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Relapsed Acute Myeloid Leukemia Drug Supply Chain Analysis
10.1 Relapsed Acute Myeloid Leukemia Drug Industry Value Chain
10.2 Relapsed Acute Myeloid Leukemia Drug Upstream Market
10.3 Relapsed Acute Myeloid Leukemia Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Relapsed Acute Myeloid Leukemia Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
Ask Our Expert

Leave This Empty:

*Required Information
List of Tables
Table 1. Key Players of Relapsed Acute Myeloid Leukemia Drug in Global Market
Table 2. Top Relapsed Acute Myeloid Leukemia Drug Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Companies, 2018-2023
Table 5. Global Relapsed Acute Myeloid Leukemia Drug Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Relapsed Acute Myeloid Leukemia Drug Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Relapsed Acute Myeloid Leukemia Drug Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
Table 9. List of Global Tier 1 Relapsed Acute Myeloid Leukemia Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Relapsed Acute Myeloid Leukemia Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2018-2023
Table 15. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2024-2030
Table 16. By Application ? Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2018-2023
Table 20. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2024-2030
Table 21. By Region ? Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2018-2023
Table 25. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), 2024-2030
Table 26. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2024-2030
Table 30. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2024-2030
Table 34. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2024-2030
Table 38. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2024-2030
Table 42. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales, (K Pcs), 2024-2030
Table 46. 4SC AG Company Summary
Table 47. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 48. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. 4SC AG Key News & Latest Developments
Table 50. AbbVie Inc. Company Summary
Table 51. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 52. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. AbbVie Inc. Key News & Latest Developments
Table 54. Actinium Pharmaceuticals, Inc. Company Summary
Table 55. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 56. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Actinium Pharmaceuticals, Inc. Key News & Latest Developments
Table 58. Agios Pharmaceuticals, Inc. Company Summary
Table 59. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 60. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Agios Pharmaceuticals, Inc. Key News & Latest Developments
Table 62. Amgen Inc. Company Summary
Table 63. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 64. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. Amgen Inc. Key News & Latest Developments
Table 66. Arog Pharmaceuticals, Inc. Company Summary
Table 67. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 68. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Arog Pharmaceuticals, Inc. Key News & Latest Developments
Table 70. Array BioPharma Inc. Company Summary
Table 71. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 72. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 73. Array BioPharma Inc. Key News & Latest Developments
Table 74. Astellas Pharma Inc. Company Summary
Table 75. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 76. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 77. Astellas Pharma Inc. Key News & Latest Developments
Table 78. Astex Pharmaceuticals, Inc. Company Summary
Table 79. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 80. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 81. Astex Pharmaceuticals, Inc. Key News & Latest Developments
Table 82. AstraZeneca Plc Company Summary
Table 83. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 84. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 85. AstraZeneca Plc Key News & Latest Developments
Table 86. AVEO Pharmaceuticals, Inc. Company Summary
Table 87. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 88. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 89. AVEO Pharmaceuticals, Inc. Key News & Latest Developments
Table 90. BioLineRx, Ltd. Company Summary
Table 91. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 92. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 93. BioLineRx, Ltd. Key News & Latest Developments
Table 94. Boehringer Ingelheim GmbH Company Summary
Table 95. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 96. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 97. Boehringer Ingelheim GmbH Key News & Latest Developments
Table 98. Boston Biomedical, Inc. Company Summary
Table 99. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 100. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 101. Boston Biomedical, Inc. Key News & Latest Developments
Table 102. Bristol-Myers Squibb Company Company Summary
Table 103. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 104. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 105. Bristol-Myers Squibb Company Key News & Latest Developments
Table 106. Calithera Biosciences, Inc. Company Summary
Table 107. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 108. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 109. Calithera Biosciences, Inc. Key News & Latest Developments
Table 110. Celgene Corporation Company Summary
Table 111. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 112. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 113. Celgene Corporation Key News & Latest Developments
Table 114. Cornerstone Pharmaceuticals, Inc. Company Summary
Table 115. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 116. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 117. Cornerstone Pharmaceuticals, Inc. Key News & Latest Developments
Table 118. CTI BioPharma Corp. Company Summary
Table 119. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Offerings
Table 120. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 121. CTI BioPharma Corp. Key News & Latest Developments
Table 122. Relapsed Acute Myeloid Leukemia Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 123. Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share of Key Manufacturers, 2021-2023
Table 124. Global Relapsed Acute Myeloid Leukemia Drug Production by Region, 2018-2023 (K Pcs)
Table 125. Global Relapsed Acute Myeloid Leukemia Drug Production by Region, 2024-2030 (K Pcs)
Table 126. Relapsed Acute Myeloid Leukemia Drug Market Opportunities & Trends in Global Market
Table 127. Relapsed Acute Myeloid Leukemia Drug Market Drivers in Global Market
Table 128. Relapsed Acute Myeloid Leukemia Drug Market Restraints in Global Market
Table 129. Relapsed Acute Myeloid Leukemia Drug Raw Materials
Table 130. Relapsed Acute Myeloid Leukemia Drug Raw Materials Suppliers in Global Market
Table 131. Typical Relapsed Acute Myeloid Leukemia Drug Downstream
Table 132. Relapsed Acute Myeloid Leukemia Drug Downstream Clients in Global Market
Table 133. Relapsed Acute Myeloid Leukemia Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Relapsed Acute Myeloid Leukemia Drug Segment by Type in 2022
Figure 2. Relapsed Acute Myeloid Leukemia Drug Segment by Application in 2022
Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Relapsed Acute Myeloid Leukemia Drug Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Relapsed Acute Myeloid Leukemia Drug Revenue, 2018-2030 (US$, Mn)
Figure 7. Relapsed Acute Myeloid Leukemia Drug Sales in Global Market: 2018-2030 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Relapsed Acute Myeloid Leukemia Drug Revenue in 2022
Figure 9. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 11. By Type - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 12. By Type - Global Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs), 2018-2030
Figure 13. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 15. By Application - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 16. By Application - Global Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs), 2018-2030
Figure 17. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 20. By Region - Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 21. By Country - North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 22. By Country - North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 23. US Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 28. Germany Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 29. France Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 37. China Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 41. India Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 43. By Country - South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 44. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share, 2018-2030
Figure 48. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Relapsed Acute Myeloid Leukemia Drug Revenue, (US$, Mn), 2018-2030
Figure 52. Global Relapsed Acute Myeloid Leukemia Drug Production Capacity (K Pcs), 2018-2030
Figure 53. The Percentage of Production Relapsed Acute Myeloid Leukemia Drug by Region, 2022 VS 2030
Figure 54. Relapsed Acute Myeloid Leukemia Drug Industry Value Chain
Figure 55. Marketing Channels

Buy Full Report

Select Licence type with your requirement and needs

SECURITY ASSUREDpayment image

analyst icon
Still not found what you want?

Speak to our Custom Research Team and get the Custom Research in a budget

Custom Research


Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

WHY CHOOSE US

  • Proactive We manage our resources 24/7 to identify issues and address them before they become problems
  • Quality & Reliability We are committed to providing reliable and highly accurate data with an excellent quality control system
  • Global Outreach 6 Major regions and 40+ countries level analysis accomplished
  • Competitive Pricing Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

SAMPLE REPORT INCLUDES
  • Industry Market SizeIndustry Market Size
  • SWOT AnalysisSWOT Analysis
  • Industry Major PlayersIndustry Major Players
  • Revenue ForecastsRevenue Forecasts
  • Historical and Forecast GrowthHistorical and Forecast Growth
  • Profitability AnalysisProfitability Analysis
SOME OF OUR CLIENTS
WHAT SET US APART?
  • quilty

    Quality Assurance

    Focus on Data Accuracy & Reliability
  • quilty

    Trusted by the Best

    75+ Clients in Fortune 500
  • quilty

    Privacy and Security

    All your transactions are secured end-to-end, ensuring a satisfactory purchase
  • quilty

    Competitive Pricing

    Ensure the best and affordable pricing
OUR HAPPY CUSTOMER Some of our customer review
Stay Updated About Relapsed Acute Myeloid Leukemia Drug and Forecast Market

Leave This Empty: